These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 32996020)
21. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients. Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y Breast Cancer Res Treat; 2020 Feb; 179(3):605-614. PubMed ID: 31768816 [TBL] [Abstract][Full Text] [Related]
22. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246 [TBL] [Abstract][Full Text] [Related]
23. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer. Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081 [TBL] [Abstract][Full Text] [Related]
24. Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. Woodward ER; van Veen EM; Forde C; Harkness EF; Byers HJ; Ellingford JM; Burghel GJ; Schlech H; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ; Gareth Evans D Genet Med; 2021 Oct; 23(10):1969-1976. PubMed ID: 34113003 [TBL] [Abstract][Full Text] [Related]
25. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study. Reiner AS; Sisti J; John EM; Lynch CF; Brooks JD; Mellemkjær L; Boice JD; Knight JA; Concannon P; Capanu M; Tischkowitz M; Robson M; Liang X; Woods M; Conti DV; Duggan D; Shore R; Stram DO; Thomas DC; Malone KE; Bernstein L; ; Bernstein JL J Clin Oncol; 2018 May; 36(15):1513-1520. PubMed ID: 29620998 [TBL] [Abstract][Full Text] [Related]
26. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations. Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916 [TBL] [Abstract][Full Text] [Related]
27. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449 [TBL] [Abstract][Full Text] [Related]
28. Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives. Vlaming M; Ausems MGEM; Schijven G; van Oort IM; Kets CM; Komdeur FL; van der Kolk LE; Oldenburg RA; Sijmons RH; Kiemeney LALM; Bleiker EMA Fam Cancer; 2024 Jun; 23(2):165-175. PubMed ID: 38722431 [TBL] [Abstract][Full Text] [Related]
29. Protein-truncating variants in moderate-risk breast cancer susceptibility genes: a meta-analysis of high-risk case-control screening studies. Aloraifi F; McCartan D; McDevitt T; Green AJ; Bracken A; Geraghty J Cancer Genet; 2015 Sep; 208(9):455-63. PubMed ID: 26250988 [TBL] [Abstract][Full Text] [Related]
30. Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis. Shi Z; Lu L; Resurreccion WK; Yang W; Wei J; Wang Q; Engelmann V; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J Prostate; 2022 Jan; 82(1):107-119. PubMed ID: 34674288 [TBL] [Abstract][Full Text] [Related]
31. Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study. Koh SJ; Ohsumi S; Takahashi M; Fukuma E; Jung KH; Ishida T; Dai MS; Chang CH; Dalvi T; Walker G; Bennett J; O'Shaughnessy J; Balmaña J Breast Cancer; 2022 Jan; 29(1):92-102. PubMed ID: 34467476 [TBL] [Abstract][Full Text] [Related]
33. Penetrance of Breast Cancer Susceptibility Genes From the eMERGE III Network. Fan X; Wynn J; Shang N; Liu C; Fedotov A; Hallquist MLG; Buchanan AH; Williams MS; Smith ME; Hoell C; Rasmussen-Torvik LJ; Peterson JF; Wiesner GL; Murad AM; Jarvik GP; Gordon AS; Rosenthal EA; Stanaway IB; Crosslin DR; Larson EB; Leppig KA; Henrikson NB; Williams JL; Li R; Hebbring S; Weng C; Shen Y; Crew KD; Chung WK JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34377931 [TBL] [Abstract][Full Text] [Related]
34. Penetrance of male breast cancer susceptibility genes: a systematic review. Chamseddine RS; Wang C; Yin K; Wang J; Singh P; Zhou J; Robson ME; Braun D; Hughes KS Breast Cancer Res Treat; 2022 Jan; 191(1):31-38. PubMed ID: 34642874 [TBL] [Abstract][Full Text] [Related]
35. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer. Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143 [TBL] [Abstract][Full Text] [Related]
36. Detection of novel germline mutations in six breast cancer predisposition genes by targeted next-generation sequencing. Dong L; Wu N; Wang S; Cheng Y; Han L; Zhao J; Long X; Mu K; Li M; Wei L; Wang W; Zhang W; Cao Y; Liu J; Yu J; Hao X Hum Mutat; 2018 Oct; 39(10):1442-1455. PubMed ID: 30039884 [TBL] [Abstract][Full Text] [Related]
37. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing. Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256 [TBL] [Abstract][Full Text] [Related]
38. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance. Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080 [TBL] [Abstract][Full Text] [Related]
39. Germline genetic variants in men with prostate cancer and one or more additional cancers. Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667 [TBL] [Abstract][Full Text] [Related]
40. Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers. Weidner AE; Liggin ME; Zuniga BI; Tezak AL; Wiesner GL; Pal T Cancer; 2020 Apr; 126(8):1651-1655. PubMed ID: 31967672 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]